ADHD

AACAP official action. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36: 85S–121S.External Source Document  

Adderall® XR prescribing information, USA. 2006.External Source Document  

American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Attention-deficit/hyperactivity disorder. In: Diagnostic and statistical manual of mental disorders. 2000, American Psychiatric Association. 85–103.External Source Document  

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006 May 5 [Epub ahead of print].External Source Document  

Barkley R. International consensus statement on ADHD. Clin Child Family Psychol Rev 2002; 5: 89–111.External Source Document  

Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237–48.External Source Document  

Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am 2004; 27: 225–32.External Source Document  

Biederman J, Kwon A, Aleardi M, Chouinard VA, Marino T, Cole H, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry 2005; 162: 1083–9.External Source Document  

Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816–8.External Source Document  

Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107: E43.External Source Document  

Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000; 105: 1158–70.External Source Document  

Cohen P, Cohen J, Kasen S, Velez CN, Hartmark C, Johnson J, et al. An epidemiological study of disorders in late childhood and adolescence–I. Age- and gender-specific prevalence. J Child Psychol Psychiatry 1993; 34: 851–67.External Source Document  Concerta® SPC, UK. 2006.External Source Document  

Cunningham CE, Barkley RA. The interactions of normal and hyperactive children with their mothers in free play and structured tasks. Child Dev 1979; 50: 217–24.External Source Document  

Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998; 56: 215–23.External Source Document  

Datamonitor, Stakeholder insight: ADHD. Prescriber attention still held by short acting stimulant drugs. DMHC2008. 2004.External Source Document  

Dexedrine tablets SPC, UK. 2005.External Source Document  

Dextrostat tablets, prescribing information, USA. 2003.External Source Document  

Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ.  Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354: 2132–3.External Source Document  

Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36: 85S–121S.External Source Document  

Equasym™XL SPC, UK. 2006.External Source Document  

Erickson JD, Schafer MK-H, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human esicular monoamine transporter. Proc Natl Acad Sci USA 1996; 93: 5166–71.External Source Document  

Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005; 116: e364–9.External Source Document  

Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951-8.External Source Document  

Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 2000; 406: 1–13.External Source Document  

Garland M, Kirkpatrick P. Atomoxetine hydrochloride. Nat Rev Drug Discov 2004; 3: 385–6.External Source Document  

Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143–6.External Source Document   

International statistical classification of diseases and related health problems, 10th Revision, version for 2006. 2006 Accessed October 2006.External Source Document  

Jones SR, Joseph JD, Barak LS, Caron MG, Wightman RM. Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 1999; 73: 2406–14.External Source Document  

King S, Griffin S, Hodges Z, Weatherly, H, Asseburg C, Richardson G, et al. Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed): Centre for Reviews and Dissemination, Centre for Health Economics, University of York; December 2004.External Source Document  

Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.External Source Document  

Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003; 4: 1165–74.External Source Document  

Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 1997; 68: 2032–37.External Source Document  

Levy F, Hay DA, Bennett KS, McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 2005; 44: 368–76.External Source Document  

Liu F, Muniz R, Minami H, Silva RR. Review and comparison of the long acting methylphenidate preparations. Psychiatr Q 2005; 76: 259–69.External Source Document  

Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 711–26.External Source Document  

Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 2003; 23: 1281–99.External Source Document  

Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25: 166–74.External Source Document  

McGough JJ, Pataki CS, Suddath R. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 2005; 5: 437–41.External Source Document  

Medikinet® retard SPC, Germany. 2005.External Source Document  

MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86.External Source Document  

National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000; 39: 182–93.External Source Document  

NICE. NICE technology appraisal guidance No 13. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. 2000. 1–13.External Source Document 

Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999; 103: 730-7.

Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 1997; 12: 527–46.

Polanczyk G, Silva de Lima M, Horta B, Biederman J, Rohde L. ADHD prevalence around the world: what are the real sources of variability in estimates? A systematic review and meta-regression analysis. In: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP). 2005.Ritalin®LA™ PI. 2004.

Ritalin®LA™ PI. 2004.

External Source Document  

Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, et al. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. Can J Psychiatry 2001; 46: 931–40.

Selikowitz M. ADHD the facts. 2004. Oxford University Press.External Source Document  

SIGN (Scottish Intercollegiate Guidelines Network). Attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. Volume 52. Edinburgh June 2001.External Source Document  

Solanto MV. The neuroscience of stimulant drug action in ADHD. In: Stimulant Drugs and ADHD Basic and Clinical Neuroscience. 2001. 355–79.Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155: 693–5.External Source Document  

Strattera (atomoxetine) SPC, UK. 2005.External Source Document  

Suzuki O, Hattori H, Asano M, Oya M, Katsuma Y. Inhibition of monoamine oxidase by d-methamphetamine. Biochem Pharmacol 1980; 29: 2070–73.External Source Document  

Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): I7–I30.External Source Document  

Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Rothenberger A, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004; 13: I7–I30.External Source Document  

Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: RC121.External Source Document   

Weiner JM, Ed. 1997, Washington, DC, American Academy of Child and Adolescent Psychiatry, American Psychiatric Press. 389–410.External Source Document  

Wasserstein J. Diagnostic issues for adolescents and adults with ADHD. J Clin Psychol 2005; 61: 535–47.External Source Document  

Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179–85.External Source Document  

Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 319–24.Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982; 222: 61-5.

Alzheimers Disease

Danysz W., and Parsons C.G. (2003) The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18(Suppl 1): 23-32.External Source Document  | Internal Use Of This Reference

Danysz W., Parsons C., Möbius H.J., Stöffler A., and Quack G. (2000) Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s Disease – A unified glutamatergic hypothesis of the mechanism of action. Neurotox Res Vol. 2: 85-97.Doody R, Wirth Y, Schmitt F, Möbius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 18: 227-232, 2004.External Source Document  | Internal Use Of This Reference

Durlach J. (1990) Magnesium depletion and pathogenesis of Alzheimer's disease. Magnes Res 3: 217-8.External Source Document  | Internal Use Of This Reference

Durlach J., Durlach V., Bac P, Bara M, and Guiet-Bara A. (1994) Magnesium and therapeutics. Magnes Res. 3-4: 313-28.External Source Document  | Internal Use Of This Reference

Fawcett W.J., Haxby E.J., and Male D.A. (1999) Magnesium: physiology and pharmacology. Br J Anaesth. 83(2): 302-20.External Source Document  | Internal Use Of This Reference

Fratiglioni L., De Ronchi D., Agüero-Torres H.(1999) Worldwide prevalence and incidence of dementia. Drugs Aging 15:365-375.External Source Document  | Internal Use Of This Reference 

Fung M.C., Weintraub M., Bowen D.L. (1995) Hypermagnesemia. Elderly over-the-counter drug users at risk. Arch Fam Med 4: 718-23.External Source Document  | Internal Use Of This Reference

Furukawa K and Mattson M.P. (1998) Secreted amyloid precursor protein alpha selectively suppresses N-methyl-D-aspartate currents in hippocampal neurons: Involvement of cyclic GMP. Neuroscience 83(2):429-38.External Source Document  | Internal Use Of This Reference

Gauthier S, Wirth Y and Möbius HJ. Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriat Psychiatr 20: 1-6, 2005. f.External Source Document  | Internal Use Of This Reference

Hallak M. (1998) Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. Magnes Res 11: 117-31.External Source Document  | Internal Use Of This Reference

Hallauer J. Institut für Gesundheitssystemforschung von der Charité Berlin, personal communication, 2002.External Source Document  | Internal Use Of This Reference

Harris M.E., Wang Y., Pedigo N.W. Jr, Hensley K., Butterfield D.A., Carney J.M. (1996) Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem. 67(1):277-86.External Source Document  | Internal Use Of This Reference

Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 18: 81-85, 2003.External Source Document  | Internal Use Of This Reference

Hartnett K.A., Stout A.K., Rajdev S., Rosenberg P.A., Reynolds I.J., Aizenman E. (1997) NMDA receptor-mediated neurotoxicity: a paradoxical requirement for extracellular Magnesium2+ in Na+/Ca2+-free solutions in rat cortical neurons in vitro. J. Neurochem. 68: 1836-45.External Source Document  | Internal Use Of This Reference

Helpern J.A., van de Linde A.M., Welch K.M., Levine S.R., Schultz L.R., Ordidge R.J., Halvorson H.R., Hugg J.W. (1993) Acute elevation and recovery of intracellular [Mg2+] following human focal cerebral ischemia. Neurology 43: 1577-81.External Source Document  | Internal Use Of This Reference

Jönsson L., Economic evaluation of treatments for Alzheimer´s Disease, 2003.External Source Document  | Internal Use Of This Reference

Jorm A.F., Korten A.E., Henderson A.S. (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica; 76:465-479.External Source Document  | Internal Use Of This Reference

Kornhuber J, Gundacker I, Maler M et al. Neurotransmitterveränderungen bei Alzheimer Demenz. In: Föstl H, Bickel H, Kurz A (Hrsg): Alzheimer Demenz–Grundlagen, Klinik und Therapie, Springer Verlag, Heidelberg, p 75-77, 1999.External Source Document  | Internal Use Of This Reference

Kornhuber J., Bormann J., Retz W., Hübers M., and Riederer P. (1989) Memantine displaces [³H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589-590.External Source Document  | Internal Use Of This Reference

Ladner C.J. and Lee J.M. (1999) Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158: 451-8.External Source Document  | Internal Use Of This Reference

Li L., Sengupta A., Haque N., Grundke-Iqbal I. and Iqbal K. (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 566: 261-269.External Source Document  | Internal Use Of This Reference

Masliah E., Raber J., Alford M., Mallory M., Mattson M.P., Yang D., Wong D., and Mucke L. (1998) Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. J Biol Chem. 273(20):12548-54.External Source Document  | Internal Use Of This Reference

Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., and Rydel R.E. (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10(2):243-54.External Source Document  | Internal Use Of This Reference

Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., and Quack G. (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 958(1):210-21.External Source Document  | Internal Use Of This Reference

Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 958:210-221, 2002.External Source Document  | Internal Use Of This Reference

Misztal M, Frankiewicz T, Parsons CG, and Danysz W. (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 296(1):1-8.External Source Document  | Internal Use Of This Reference

Misztal. M, Frankiewicz T, Parsons CG, Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid – protection by MK-801 and memantine. Eur J Pharmacol; 296: 1-8, 1996.External Source Document  | Internal Use Of This Reference

 Müller W.E., Mutschler E., and Riederer P. (1995) Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 28:113-124.External Source Document  | Internal Use Of This Reference

Noda M, Nakanishi H, and Akaike N. (1999) Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 92(4):1465-74.External Source Document  | Internal Use Of This Reference

Parsons C.G., Danysz W., and Quack G. (1995) Glutamate in CNS Disorders as a target for drug development: An update. Drug News Perspect 11(9): 523-569.External Source Document  | Internal Use Of This Reference

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) rezeptor antagonist – a review of preclinical data. Neuropharmacology; 38:735 – 767, 199.External Source Document  | Internal Use Of This Reference

 Reisberg B, Doody R, Stöffler A et al. Memantine in moderate-to-severe Alzheimer´s disease. N Engl J Med 348: 1333-1341, 2003.External Source Document  | Internal Use Of This Reference

Reynolds I.J. (1998) Intracellular calcium and magnesium: critical determinants of excitotoxicity? Prog Brain Res 116: 225-43.External Source Document  | Internal Use Of This Reference

 Stieg PE, Sathi S,Warach S, Le DA, Lipton SA. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol. 30; 375(1– 3):115 – 20, 1999.External Source Document  | Internal Use Of This Reference

Stommel M., Collins C.E. and Given B.A. (1994) The costs of family contributions to the care of persons with dementia. The Gerontologist, Vol 34, 2 199-205.External Source Document  | Internal Use Of This Reference

 Tariot PN, Farlow MR, Grossberg GT et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil. JAMA 291: 317-324, 2004.External Source Document  | Internal Use Of This Reference

Wenk G.L., Danysz W., and Mobley S.L. (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293(3):267-70.External Source Document  | Internal Use Of This Reference

Wenk G.L., Danysz W., and Roice D.D. (1996) The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7(9):1453-6.External Source Document  | Internal Use Of This Reference

Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 655: 7-11, 1994.External Source Document  | Internal Use Of This Reference

Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293: 267-270, 1995.External Source Document  | Internal Use Of This Reference

Wenk GL, Danysz W, Roice DD. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7: 1453-1456, 1996.External Source Document  | Internal Use Of This Reference

Willard L.B., Hauss-Wegrzyniak B., Danysz W., and Wenk G.L. (2000) The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134: 58-65.External Source Document  | Internal Use Of This Reference

Willard LB, Hauss-Wegrzyniak B, Danysz W,Wenk GL. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134: 58 – 65, 2000.External Source Document  | Internal Use Of This Reference

Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer´s disease. Pharmacoeconomics 21(3): 327-340, 2003.External Source Document  | Internal Use Of This Reference

Wimo A., Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wetterholm A.L. Mastey V., Haglund A., Zhang R., Miceli R., Chin W., Subbiah P. for the Donepezil Noridc Study Group. (2003) An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-year, Double-blind, Randomized Trial.Dement Geriatr Cogn Disord 2003; 15:44-54. Erratum: Dement Geriatr Cogn Disord.;16:102.External Source Document  | Internal Use Of This Reference

Wimo A., Winblad B., Stöffler A., Wirth Y. and Möbius H.J. (2003) Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. PharmacoEconomics; 21: 327-340.External Source Document  | Internal Use Of This Reference

Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (Benefit and Efficacy in Severely demented patients during Treatment with Memantine). Int J Geriat Psychiatry 14: 135-146, 1999.External Source Document  | Internal Use Of This Reference

Worlds Population Prospects: The 2002 Revision Highlights. ESA/P/WP.180, 26 February 2003.External Source Document  | Internal Use Of This Reference

Wu J., Anwyl R., and Rowan M.J. (1995) Beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6(17): 2409-2413.External Source Document  | Internal Use Of This Reference

Zajaczkowski W., Frankiewicz T., Parsons C.G., and Danysz W. (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36(7): 961-71. External Source Document  | Internal Use Of This Reference

Arthritis

Jordan K M, Arden N K, Doherty M, Bannwarth B, et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62;1145-1155. doi:10.1136/ard.2003.011742.External Source Document  | Internal Use Of This Reference

Cardiovascular Safety of NSAIDs - Review of Evidence. External Source Document  | Internal Use Of This Reference

Questions and Answers on non-selective NSAIDs / CHMP review of safety of non-selective NSAIDs. External Source Document  | Internal Use Of This Reference

Altman R, Alarcon G, Appelrouth D, Bloch D, et al.  The American College of Rheumatology Criteria for the Classification and Reporting of Osteoarthritis of the Hand. USA, Vol.33:No.11 (1990).External Source Document  | Internal Use Of This Reference

Altman R, Alarcon G, Appelrouth D, Bloch D, et al.  The American College of Rheumatology Criteria for the Classification and Reporting of Osteoarthritis of the Hip. USA, Vol.34:No.5 (1991).External Source Document  | Internal Use Of This Reference

Jordan K M, Arden N K, Doherty M, Bannwarth B, et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62;1145-1155. doi:10.1136/ard.2003.011742.External Source Document  | Internal Use Of This Reference

Asthma

Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH, Forbes AB, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001;163:12–18.External Source Document  | Internal Use Of This Reference

Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006 Aug;100(8):1297-306.External Source Document | Internal Use Of This Reference

Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227–1236.External Source Document | Internal Use Of This Reference

Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998;12(1):130-5.External Source Document | Internal Use Of This Reference

Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005;115:940–945.External Source Document | Internal Use Of This Reference

Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112:S1–S40.External Source Document | Internal Use Of This Reference

ASMANEX TWISTHALER product information.External Source Document | Internal Use Of This Reference

Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000;19:215-8.External Source Document | Internal Use Of This Reference

Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102(4 Pt 1):531-8.External Source Document | Internal Use Of This Reference

Bateman E, Karpel J, Casale T, Wenzel S, Banerji D. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006;129:1176–1187.External Source Document | Internal Use Of This Reference

Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109:S482–S489.External Source Document |

Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007;98:118–127.External Source Document | Internal Use Of This Reference

Bisgaard H. Delivery of inhaled medication to children. J Asthma 1997;34(6):443-67.External Source Document |

Atopic Dermatitis

• Prevalence of Atopic Dermatitis
• Management of Atopic Dermatitis
• Treatment Options for Atopic Dermatitis
• Atopic Dermatitis Resources

CONNECT

• EPG Mobile
• Congress Diary

DISEASE CENTRES

• Post-MI Heart Failure
• Prostate Cancer
• Renal Cell Carcinoma
• Multiple Sclerosis
• Men's Health

  CongresseshomeMen's healthDefinitionPrevalenceSymptomsClinical examinationLaboratory testingPatient based Physical examinationSpecialized diagnostic testsHow erection worksProblems with erectionLifestyleMedicationMetabolic SyndromeOverviewProstatectomyTestosterone Deficiency and HypogonadismAlgorithmFirst- line therapySecond-line therapyThird-line therapyDurationED & DiabetesED & DyslipidemiaED & HypertensionED & metabolic syndromeED & Radical ProstatectomyED & The Role of Female PartnerFast onsetFirst dose SuccessHardnessMode of ActionPERTPharmacokineticsPharmacologyReceptor AffinityReliabilitySafety & TolerabilityDiagnosis - Diagnosis and Treatment AlgorithmDiagnosis - Symptoms, Physical Examination, Blood TestsEtiology - Etiology Of HypogonadismEtiology - Late Onset HypogonadismEtiology - Primary and Secondary HyponadismEtiology - Risk Factors For HypogonadismOverview - Current treatment and controversiesOverview - How are men affected by hypogonadism?Overview - How important is it to treat hypogonadismOverview - Hypogonadism DefinedOverview - Hypogonadism PrevalenceDiagnosis - Symptoms, Physical Examination, Blood TestsTreatment Options - Safety Of Testosterone Replacement TherapyTreatment Options - What Are The Benefits Of Treating Hypogonadism?Treatment Options - What Treatments Are Available?Treatment OptionsLatest UpdatesTestogel reduces fat and improves bodyTestosterone improves functional performanceTestosterone reduces visceral fatAssociations & OrganisationsFurther Reading - Erectile DysfunctionFurther Reading - Hypogonadism

• Atopic Dermatitis
• Neuropathic Pain
• Soft Tissue Sarcoma
• Niemann-Pick Type C
• Cystic Fibrosis
• Cholesterol
• Contraception
• Hepatitis
• Renal Anaemia
• CML
• GIST
• Parkinsons
• Insomnia
• Asthma
• LSD’s
• NSCLC
• Alzheimer's
• Diabetes
• Opioids and Pain
• Arthritis
• Hypertension
• Migraine
• Cervical Cancer
• Ophthalmics

AFFILIATE PARTNERS

• Thrombosis
• Hereditary Angioedema

QUICK SEARCH

• ADHD
• Alzheimers
• Anxiety Disorders
• Arthritis
• Asthma
• Avonex
• Beta-feron
• Breast Cancer
• Cervical Cancer
• Cholesterol
• Colorectal Cancer
• Copaxone
• Depression
• Diabetes
• Erectile Dysfunction
• Extavia
• Hypertension
• Insomnia
• Men's Health
• Meningitis
• Migraine
• Pain Management
• Parkinson's
• Pharma News
• Post-MI
• Pregnancy
• Rebif
• Renal anaemia
• Renal Cell Carcinoma
• Thrombosis
• Thromboembolism
• Tysabri

GUIDELINES

• Acne
• Anaemia
• Common bile duct
• Dental
• Genital Tract Infections
• Head Injury
• Heart Disease
• Hypertension
• Irritable bowel syndrome
• Postnatal health
• Rhinitis
• Warts

DRUG DATA

• Deutsch    
• English
• Español
• Norsk
• Nederlands
• Svenska
• Français
• Português
• Italiano

REFERENCES

• ADHD to Diabetes    
• GIST to HPV
• Hypertension to Migraine
• Niemann-Pick to Parkinsons
• Renal Anaemia to Thrombosis